ProQR Therapeutics ROA 2024

ProQR Therapeutics Aktienanalyse

What does ProQR Therapeutics do?

ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight. ProQR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding ProQR Therapeutics's Return on Assets (ROA)

ProQR Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing ProQR Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider ProQR Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in ProQR Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about ProQR Therapeutics stock

What is the Return on Assets (ROA) of ProQR Therapeutics this year?

The Return on Assets (ROA) of ProQR Therapeutics is -0.2 undefined this year.

What was the ROA of ProQR Therapeutics compared to the previous year?

The ROA of ProQR Therapeutics has increased by -46.35% compared to the previous year.

What consequences do high ROA have for investors of ProQR Therapeutics?

A high ROA is advantageous for investors of ProQR Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in ProQR Therapeutics?

A low ROA can be unfavorable for investors of ProQR Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of ProQR Therapeutics affect the company?

An increase in ROA of ProQR Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of ProQR Therapeutics impact the company?

A reduction in the ROA of ProQR Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of ProQR Therapeutics?

Some factors that can influence the ROA of ProQR Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of ProQR Therapeutics important for investors?

The ROA of ProQR Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can ProQR Therapeutics take to improve ROA?

To improve ROA, ProQR Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does ProQR Therapeutics pay?

Over the past 12 months, ProQR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ProQR Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of ProQR Therapeutics?

The current dividend yield of ProQR Therapeutics is .

When does ProQR Therapeutics pay dividends?

ProQR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ProQR Therapeutics?

ProQR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ProQR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is ProQR Therapeutics located?

ProQR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ProQR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ProQR Therapeutics from 11/5/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did ProQR Therapeutics pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of ProQR Therapeutics in the year 2023?

In the year 2023, ProQR Therapeutics distributed 0 EUR as dividends.

In which currency does ProQR Therapeutics pay out the dividend?

The dividends of ProQR Therapeutics are distributed in EUR.